Progress in bipolar disorder drug design toward the development of novel therapeutic targets: a clinician’s perspective

References

• Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord. 2009;11(3):225–255.
   PubMed Web of Science ®Google Scholar
• McIntyre RS. Treatment-resistant mood disorders. New york, USA:Oxford Psychiatry Library; 2014.
   Google Scholar
• Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. New England J Med. 2007;356(17):1711–1722.
   PubMed Web of Science ®Google Scholar
• Zarate CA, Quiroz JA. Combination treatment in bipolar disorder: a review of controlled trials. Bipolar Disord. 2003;5(3):217–225.
   PubMed Web of Science ®Google Scholar
• Sachs GS. Unmet clinical needs in bipolar disorder. J Clin Psychopharmacol. 2003;23(3):SS2-S8.
   Web of Science ®Google Scholar
• Fornaro M, Martino M, De Pasquale C, et al. The argument of antidepressant drugs in the treatment of bipolar depression: mixed evidence or mixed states? Expert Opin Pharmacother. 2012;13(14):2037–2051.
   PubMed Web of Science ®Google Scholar
• Freeman MP, Freeman SA, McElroy SL. The comorbidity of bipolar and anxiety disorders: prevalence, psychobiology, and treatment issues. J Affect Disord. 2002;68(1):1–23.
   PubMed Web of Science ®Google Scholar
• Fornaro M, Nardi AE, De Berardis D, et al. Experimental drugs for bipolar psychosis. Expert Opin Investig Drugs. 2016;25(12):1371–1375.
   PubMed Web of Science ®Google Scholar
• Stromgaard K, Krogsgaard-Larsen P, Madsen U. Textbook of drug design and discovery, Fifth Edition. London, UK: CRC Press; 2016.
   Google Scholar
• Tollenaere J. The role of structure-based ligand design and molecular modelling in drug discovery. Pharm World Sci. 1996;18(2):56–62.
   PubMedGoogle Scholar
• Dixon SJ, Stockwell BR. Identifying druggable disease-modifying gene products. Curr Opin Chem Biol. 2009;13(5–6):549–555.
   PubMed Web of Science ®Google Scholar
• Xiong C, Van Belle G, Miller JP, et al. Designing clinical trials to test disease-modifying agents: application to the treatment trials of Alzheimer’s disease. Clin Trials. 2011;8(1):15–26.
   PubMed Web of Science ®Google Scholar
• McGhee DJ, Ritchie CW, Zajicek JP, et al. A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer’s disease and Parkinson’s disease. BMC Neurol. 2016;16(1):92.
   PubMedGoogle Scholar
• Anderson AC. The process of structure-based drug design. Chem Biol. 2003;10(9):787–797.
   PubMed Web of Science ®Google Scholar
• Recanatini M, Bottegoni G, Cavalli A. In silico antitarget screening. Drug Discov Today Technol. 2004;1(3):209–215.
   PubMedGoogle Scholar
• Ganellin CR, Jefferis R, Roberts SM. Introduction to biological and small molecule drug research and development: theory and case studies. Oxford, UK: Academic Press; 2013.
   Google Scholar
• Yuan Y, Pei J, Lai L. Binding site detection and druggability prediction of protein targets for structure-based drug design. Curr Pharm Des. 2013;19(12):2326–2333.
   PubMed Web of Science ®Google Scholar
• Healy D. Mania: a short history of bipolar disorder. Maryland, USA:JHU Press; 2008.
   Google Scholar
• Klein DF. The loss of serendipity in psychopharmacology. Jama. 2008;299(9):1063–1065.
   PubMed Web of Science ®Google Scholar
• Rosenberg G. The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees? Cell Mol Life Sci. 2007;64(16):2090–2103.
   PubMed Web of Science ®Google Scholar
• Rybakowski JK. Genetic influences on response to mood stabilizers in bipolar disorder. CNS Drugs. 2013;27(3):165–173.
   PubMed Web of Science ®Google Scholar
• Chen G, Pan B, Hawver DB, et al. Attenuation of cyclic AMP production by carbamazepine. J Neurochem. 1996;67(5):2079–2086.
   PubMed Web of Science ®Google Scholar
• Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry. 1999;156(5):702–709.
   PubMed Web of Science ®Google Scholar
• Fornaro M, De Berardis D, Perna G, et al. Lurasidone in the treatment of bipolar depression: systematic review of systematic reviews. Biomed Res Int. 2017;2017:1–17.
   Google Scholar
• Solmi M, Murru A, Pacchiarotti I, et al. Safety, tolerability, and risks associated with first-and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017;13:757–777.
   PubMed Web of Science ®Google Scholar
• Fornaro M, Aguglia E, Dell’Osso L, et al. Could the underestimation of bipolarity obstruct the search for novel antidepressant drugs? Expert Opin Pharmacother. 2011;12(18):2817–2831.
   PubMed Web of Science ®Google Scholar
• Fornaro M, Giosue P. Current nosology of treatment resistant depression: a controversy resistant to revision. Clin Pract Epidemiol Ment Health. 2010 May 4;6:20–24. DOI:10.2174/1745017901006010020
   PubMedGoogle Scholar
• Undurraga J, Baldessarini RJ, Valentí M, et al. Bipolar depression: clinical correlates of receiving antidepressants. J Affect Disord. 2012;139(1):89–93.
   PubMed Web of Science ®Google Scholar
• Scherk H, Pajonk FG, Leucht S. Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry. 2007;64(4):442–455.
   PubMed Web of Science ®Google Scholar
• Malhi GS, Adams D, Berk M. Medicating mood with maintenance in mind: bipolar depression pharmacotherapy. Bipolar Disord. 2009;11(s2):55–76.
   PubMedGoogle Scholar
• Fornaro M, Stubbs B, De Berardis D, et al. Does the “Silver Bullet” lose its shine over the time? Assessment of loss of lithium response in a preliminary sample of bipolar disorder outpatients. Clin Pract Epidemiol Ment Health. 2016;12:142–157.
   PubMedGoogle Scholar
• Prien RF, Caffey EM, Klett CJ. Comparison of lithium carbonate and chlorpromazine in the treatment of mania: report of the Veterans Administration and National Institute of Mental Health Collaborative Study Group. Arch Gen Psychiatry. 1972;26(2):146–153.
   PubMedGoogle Scholar
• Cruceanu C, Alda M, Turecki G. Lithium: a key to the genetics of bipolar disorder. Genome Med. 2009;1(8):79.
   PubMedGoogle Scholar
• Singh N, Sharpley AL, Emir UE, et al. Effect of the putative lithium mimetic ebselen on brain myo-inositol, sleep and emotional processing in humans. Neuropsychopharmacology. 2016;41(7):1768–1778.
   PubMed Web of Science ®Google Scholar
• Freland L, Beaulieu J-M. Inhibition of GSK3 by lithium, from single molecules to signaling networks. Front Mol Neurosci. 2012;5.
   PubMed Web of Science ®Google Scholar
• Gould TD, Manji HK. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology. 2005;30(7):1223–1237.
   PubMed Web of Science ®Google Scholar
• Patel P, Woodgett JR. Chapter eight-glycogen synthase kinase 3: a kinase for all pathways? Curr Top Dev Biol. 2017;123:277–302.
   PubMed Web of Science ®Google Scholar
• Jope RS. Glycogen synthase kinase-3 in the etiology and treatment of mood disorders. Front Mol Neurosci. 2011;4.
   Web of Science ®Google Scholar
• Yadranji Aghdam S, Barger SW. Glycogen synthase kinase-3 in neurodegeneration and neuroprotection: lessons from lithium. Curr Alzheimer Res. 2007;4(1):21–31.
   PubMed Web of Science ®Google Scholar
• Marmol F. Lithium: bipolar disorder and neurodegenerative diseases Possible cellular mechanisms of the therapeutic effects of lithium. Prog Neuro-Psychopharmacology Biol Psychiatry. 2008;32(8):1761–1771.
   PubMed Web of Science ®Google Scholar
• Bowden CL, Swann AC, Calabrese JR, et al. Maintenance clinical trials in bipolar disorder: design implications of the divalproex-lithium-placebo study. Psychopharmacol Bull. 1997;33(4):693.
   PubMedGoogle Scholar
• Tohen M, Frank E, Bowden CL, et al. The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disord. 2009;11(5):453–473.
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Rapport DJ, Shelton MD, et al. Evolving methodologies in bipolar disorder maintenance research. Br J Psychiatry. 2001;178(41):s157–s163.
   PubMedGoogle Scholar
• Carvalho AF, Vieta E. The treatment of bipolar disorder: integrative clinical strategies and future directions. New York, USA: Oxford University Press; 2017.
   Google Scholar
• Berk M. Neuroprogression: pathways to progressive brain changes in bipolar disorder. Int J Neuropsychopharmacol. 2009;12(4):441–445.
   PubMed Web of Science ®Google Scholar
• Berk M, Conus P, Lucas N, et al. Setting the stage: from prodrome to treatment resistance in bipolar disorder. Bipolar Disord. 2007;9(7):671–678.
   PubMed Web of Science ®Google Scholar
• Konstantakopoulos G. Challenges with bipolar disorder drug discovery. Oxford, UK: Taylor & Francis; 2016.
   Google Scholar
• Fornaro M. Beyond monoamines towards the development of novel antidepressants. J Psychopathology. 2012;18:226–233.
   Google Scholar
• Krystal JH, Sanacora G, Blumberg H, et al. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol Psychiatry. 2002;7(S1):SS71–S80.
   Google Scholar
• Zarate CA, Singh J, Manji HK. Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol Psychiatry. 2006;59(11):1006–1020.
   PubMed Web of Science ®Google Scholar
• Sanacora G, Zarate CA Jr, Krystal J, et al. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov. 2008;7(5):426–437.
   PubMed Web of Science ®Google Scholar
• Riedel G, Platt B, Micheau J. Glutamate receptor function in learning and memory. Behav Brain Res. 2003;140(1–2):1–47.
   PubMed Web of Science ®Google Scholar
• Partin KM. AMPA receptor potentiators: from drug design to cognitive enhancement. Curr Opin Pharmacol. 2015;20:46–53.
   PubMed Web of Science ®Google Scholar
• van Wissen K, Blanchard D. Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults. Issues Ment Health Nurs. 2017;38(6):526–527.
   PubMed Web of Science ®Google Scholar
• Veronese N, Solmi M, Luchini C, et al. Acetylcholinesterase inhibitors and memantine in bipolar disorder: a systematic review and best evidence synthesis of the efficacy and safety for multiple disease dimensions. J Affect Disord. 2016;197:268–280.
   PubMed Web of Science ®Google Scholar
• Park LT, Lener MS, Hopkins M, et al. A double-blind, placebo-controlled, pilot study of riluzole monotherapy for acute bipolar depression. J Clin Psychopharmacol. 2017;37(3):355–358.
   PubMed Web of Science ®Google Scholar
• Naughton M, Clarke G, Olivia F, et al. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action. J Affect Disord. 2014;156:24–35.
   PubMed Web of Science ®Google Scholar
• Luckenbaugh DA, Niciu MJ, Ionescu DF, et al. Do the dissociative side effects of ketamine mediate its antidepressant effects? J Affect Disord. 2014;159:56–61.
   PubMed Web of Science ®Google Scholar
• Yang C, Shirayama Y, Zhang J, et al. R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry. 2015;5(9):e632.
   PubMed Web of Science ®Google Scholar
• Zarate CA, Niciu MJ. Ketamine for depression: evidence, challenges and promise. World Psychiatry. 2015;14(3):348–350.
   PubMed Web of Science ®Google Scholar
• Chen S-L, Lee S-Y, Chang Y-H, et al. Therapeutic effects of add-on low-dose dextromethorphan plus valproic acid in bipolar disorder. Eur Neuropsychopharmacol. 2014;24(11):1753–1759.
   PubMed Web of Science ®Google Scholar
• Carta MG, Bhat KM, Preti A. GABAergic neuroactive steroids: a new frontier in bipolar disorders? Behav Brain Funct. 2012;8(1):61.
   PubMed Web of Science ®Google Scholar
• Zarate CA, Quiroz JA, Singh JB, et al. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry. 2005;57(4):430–432.
   PubMed Web of Science ®Google Scholar
• Je Jeon W, Dean B, Scarr E, et al. The role of muscarinic receptors in the pathophysiology of mood disorders: a potential novel treatment? Curr Neuropharmacol. 2015;13(6):739–749.
   PubMed Web of Science ®Google Scholar
• Chen J, Lu Z, Zhang M, et al. A randomized, 4-week double-blind placebo control study on the efficacy of donepezil augmentation of lithium for treatment of acute mania. Neuropsychiatr Dis Treat. 2013;9:839.
   PubMed Web of Science ®Google Scholar
• van Enkhuizen J, Milienne-Petiot M, Geyer MA, et al. Modeling bipolar disorder in mice by increasing acetylcholine or dopamine: chronic lithium treats most, but not all features. Psychopharmacology. 2015;232(18):3455–3467.
   PubMed Web of Science ®Google Scholar
• Alexis Geoffroy P, Etain B, Franchi J-AM, et al. Melatonin and melatonin agonists as adjunctive treatments in bipolar disorders. Curr Pharm Des. 2015;21(23):3352–3358.
   PubMed Web of Science ®Google Scholar
• Mahableshwarkar AR, Calabrese JR, Macek TA, et al. Efficacy and safety of sublingual ramelteon as an adjunctive therapy in the maintenance treatment of bipolar I disorder in adults: a phase 3, randomized controlled trial. J Affect Disord. 2017;221:275–282.
   PubMed Web of Science ®Google Scholar
• Gallagher P, Malik N, Newham J, et al. Antiglucocorticoid treatments for mood disorders. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD005168. DOI:10.1002/14651858.CD005168.pub2.
   Google Scholar
• Howland RH. Mifepristone as a therapeutic agent in psychiatry. J Psychosoc Nurs Ment Health Serv. 2013;51(6):11–14.
   Web of Science ®Google Scholar
• Arabzadeh S, Ameli N, Zeinoddini A, et al. Celecoxib adjunctive therapy for acute bipolar mania: a randomized, double‐blind, placebo‐controlled trial. Bipolar Disord. 2015;17(6):606–614.
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ. Potential novel treatments for bipolar depression: ketamine, fatty acids, anti-inflammatory agents, and probiotics. CNS Neurol Disord Drug Targets. 2017;16:211–216.
   Web of Science ®Google Scholar
• Olsson SK, Sellgren C, Engberg G, et al. Cerebrospinal fluid kynurenic acid is associated with manic and psychotic features in patients with bipolar I disorder. Bipolar Disord. 2012;14(7):719–726.
   PubMed Web of Science ®Google Scholar
• Mansour HA, Monk TH, Nimgaonkar VL. Circadian genes and bipolar disorder. Ann Med. 2005;37(3):196–205.
   PubMed Web of Science ®Google Scholar
• Nievergelt CM, Kripke DF, Barrett TB, et al. Suggestive evidence for association of the circadian genes PERIOD3 and ARNTL with bipolar disorder. Am J Med Genet B: Neuropsychiatric Genet. 2006;141(3):234–241.
   Google Scholar
• Gao Z-G, Jacobson KA. Allosteric modulation and functional selectivity of G protein-coupled receptors. Drug Discov Today Technol. 2013;10(2):e237–e243.
   PubMedGoogle Scholar
• De Berardis D, Marini S, Fornaro M, et al. The melatonergic system in mood and anxiety disorders and the role of agomelatine: implications for clinical practice. Int J Mol Sci. 2013;14(6):12458–12483.
   PubMed Web of Science ®Google Scholar
• Daban C, Vieta E, Mackin P, et al. Hypothalamic-pituitary-adrenal axis and bipolar disorder. Psychiatr Clin. 2005;28(2):469–480.
   Google Scholar
• Rapoport SI, Bosetti F. Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder? Arch Gen Psychiatry. 2002;59(7):592–596.
   PubMedGoogle Scholar
• Rosenblat JD, Kakar R, Berk M, et al. Anti‐inflammatory agents in the treatment of bipolar depression: a systematic review and meta‐analysis. Bipolar Disord. 2016;18(2):89–101.
   PubMed Web of Science ®Google Scholar
• Waterdrinker A, Berk M, Venugopal K, et al. Effects of N-Acetyl cysteine on suicidal ideation in bipolar depression. J Clin Psychiatry. 2015;76(5):665.
   PubMed Web of Science ®Google Scholar
• Toniolo RA, Fernandes FBF, Silvia M, et al. Cognitive effects of creatine monohydrate adjunctive therapy in patients with bipolar depression: results from a randomized, double-blind, placebo-controlled trial. J Affect Disord. 2017;224:69–75.
   Google Scholar
• Yoon SJ, Lyoo IK, Haws C, et al. Decreased glutamate/glutamine levels may mediate cytidine’s efficacy in treating bipolar depression: a longitudinal proton magnetic resonance spectroscopy study. Neuropsychopharmacology. 2009;34(7):1810–1818.
   PubMed Web of Science ®Google Scholar
• Ong WY, Farooqui T, Kokotos G, et al. Synthetic and natural inhibitors of phospholipases A2: their importance for understanding and treatment of neurological disorders. ACS Chem Neurosci. 2015;6(6):814–831.
   PubMed Web of Science ®Google Scholar
• Chowdhury MI, Hasan M, Islam MS, et al. Elevated serum MDA and depleted non-enzymatic antioxidants, macro-minerals and trace elements are associated with bipolar disorder. J Trace Elem Med Biol. 2017;39:162–168.
   PubMed Web of Science ®Google Scholar
• Iwahashi K, Nishizawa D, Narita S, et al. Haplotype analysis of GSK-3β gene polymorphisms in bipolar disorder lithium responders and nonresponders. Clin Neuropharmacol. 2014;37(4):108–110.
   PubMed Web of Science ®Google Scholar
• Vasconcelos-Moreno MP, Fries GR, Gubert C, et al. Telomere length, oxidative stress, inflammation and BDNF levels in siblings of patients with bipolar disorder: implications for accelerated cellular aging. Int J Neuropsychopharmacol. 2017;20(6):445–454.
   PubMed Web of Science ®Google Scholar
• Soczynska JK, Kennedy SH, Alsuwaidan M, et al. A pilot, open‐label, 8‐week study evaluating the efficacy, safety and tolerability of adjunctive minocycline for the treatment of bipolar I/II depression. Bipolar Disord. 2017;19(3):198–213.
   PubMed Web of Science ®Google Scholar
• Dean OM, Turner A, Malhi G, et al. Design and rationale of a 16-week adjunctive randomized placebo-controlled trial of mitochondrial agents for the treatment of bipolar depression. Rev Bras Psiquiatr. 2015;37(1):03–12.
   PubMed Web of Science ®Google Scholar
• Bartoli F, Crocamo C, Clerici M, et al. Allopurinol as add-on treatment for mania symptoms in bipolar disorder: systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry. 2017;210(1):10–15.
   PubMed Web of Science ®Google Scholar
• Zarate CA, Manji HK. Putative drugs and targets for bipolar disorder. Mt Sinai J Med. 2008;75(3):226–247.
   PubMedGoogle Scholar
• Amoruso A, Bardelli C, Cattaneo CI, et al. Neurokinin (NK)-1 receptor expression in monocytes from bipolar disorder patients: a pilot study. J Affect Disord. 2015;178:188–192.
   PubMed Web of Science ®Google Scholar
• Fries GR, Valvassori SS, Bock H, et al. Memory and brain-derived neurotrophic factor after subchronic or chronic amphetamine treatment in an animal model of mania. J Psychiatr Res. 2015;68:329–336.
   PubMed Web of Science ®Google Scholar
• Berk M, Brnabic A, Dodd S, et al. Does stage of illness impact treatment response in bipolar disorder? Empirical treatment data and their implication for the staging model and early intervention. Bipolar Disord. 2011;13(1):87–98.
   PubMed Web of Science ®Google Scholar
• Dimitrakopoulos S, Konstantakopoulos G. Pharmacological agents under research for the maintenance treatment in bipolar disorder. Psychiatriki. 2015 Jul-Sep;26(3):169–180. PubMed PMID: 26480221.
   PubMedGoogle Scholar
• Peedicayil J. Epigenetic approaches for bipolar disorder drug discovery. Expert Opin Drug Discov. 2014;9(8):917–930.
   PubMed Web of Science ®Google Scholar
• Lavebratt C, Olsson S, Backlund L, et al. The KMO allele encoding Arg452 is associated with psychotic features in bipolar disorder type 1, and with increased CSF KYNA level and reduced KMO expression. Mol Psychiatry. 2014;19(3):334–341.
   PubMed Web of Science ®Google Scholar
• Shioya A, Saito Y, Arima K, et al. Neurodegenerative changes in patients with clinical history of bipolar disorders. Neuropathology. 2015;35(3):245–253.
   PubMed Web of Science ®Google Scholar
• Sanches M, Soares JC. New drugs for bipolar disorder. Curr Psychiatry Rep. 2011 Dec;13(6):513–521. DOI:10.1007/s11920-011-0231-1. PubMed PMID: 21877160.
   PubMed Web of Science ®Google Scholar
• Goodwin FK, Jamison KR. Manic-depressive illness: bipolar disorders and recurrent depression. Vol. 1. Oxford, UK: Oxford University Press; 2007.
   Google Scholar
• Fornaro M, Stubbs B, De Berardis D, et al. Atypical antipsychotics in the treatment of acute bipolar depression with mixed features: a systematic review and exploratory meta-analysis of placebo-controlled clinical trials. Int J Mol Sci. 2016 Feb 16;17(2):241. PubMed PMID: 26891297; PubMed Central PMCID: PMCPMC4783972. DOI:10.3390/ijms17020241
   PubMed Web of Science ®Google Scholar
• Fernandes BS, Williams LM, Steiner J, et al. The new field of ‘precision psychiatry’. BMC Med. 2017;15(1):80.
   PubMedGoogle Scholar
• Perugi G, Fornaro M. Bipolar disorder treatment guidelines and their limits in every day clinical practice. Giorn Ital Psicopatl. 2011;17(3):261–264.
   Google Scholar
• Soares JC, Young AH. Bipolar disorders: basic mechanisms and therapeutic implications. 3rd. Oxford, UK: CRC Press; 2017.
   Google Scholar
• Zohar J, Nutt DJ, Kupfer DJ, et al. A proposal for an updated neuropsychopharmacological nomenclature. Eur Neuropsychopharmacol. 2014 Jul;24(7):1005–1014. PubMed PMID: 24630385. DOI:10.1016/j.euroneuro.2013.08.004
   PubMed Web of Science ®Google Scholar
• Bowden CL. Bipolar pathophysiology and development of improved treatments. Brain Res. 2008;1235:92–97.
   PubMed Web of Science ®Google Scholar
• Fountoulakis KN, Vieta E, Young A, et al. The International College of Neuropsychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), part 4: unmet needs in the treatment of bipolar disorder and recommendations for future research. Int J Neuropsychopharmacol. 2017;20(2):196–205.
   PubMed Web of Science ®Google Scholar